Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELOTA: JNJ-88545223 in Active Psoriatic Arthritis
ChiCTR2600118186Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JNJ-88545223 in psoriatic arthritis (PsA) and plaque psoriasis (4 arms), sponsored by Peking University People's Hospital. Primary endpoint: ACR50 response at Week 16. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
JNJ-88545223
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2600118186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118186.